List view / Grid view
Several countries have temporarily stopped the use of the vaccine while reports of blood clots are investigated by the EMA’s pharmacovigilance committee and other authorities.
An interim analysis reveals the Covaxin® (BBV152) vaccine was relatively safe and 81 percent effective in preventing symptomatic COVID-19.
The European Medicines Agency has set out its guidelines for vaccine manufacturers adapting their approved COVID-19 vaccines to combat viral variants.
The Emergency Use Listing will allow doses of the COVID-19 vaccines to be distributed through COVAX, the WHO’s vaccine allocation facility.
COVAX has allocated 90 million doses of AstraZeneca’s COVID-19 vaccine and 320,000 doses of the Pfizer-BioNTech vaccine to African countries.
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803-300x278.jpg)
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803.jpg)
A preliminary analysis suggests the COVID-19 Vaccine AstraZeneca was 74 percent effective after the first dose and 82 percent effective with a 12-week inter-dose interval.
The committee for human medicinal products recommended AstraZeneca’s COVID-19 vaccine be granted conditional marketing authorisation alongside 12 other approvals.
The EMA's human medicines committee has initiated a rolling review of AstraZeneca's COVID-19 vaccine candidate to test its efficacy.
